Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Factor VIII antibody

The Mouse Monoclonal anti-Factor VIII antibody has been validated for WB, IHC (fro) and EIA. It is suitable to detect Factor VIII in samples from Human.
Catalog No. ABIN112268

Quick Overview for Factor VIII antibody (ABIN112268)

Target

See all Factor VIII (F8) Antibodies
Factor VIII (F8) (Coagulation Factor VIII (F8))

Reactivity

  • 103
  • 62
  • 31
  • 18
  • 11
  • 6
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
Human

Host

  • 101
  • 21
  • 9
  • 2
Mouse

Clonality

  • 113
  • 20
Monoclonal

Conjugate

  • 56
  • 20
  • 17
  • 7
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
This Factor VIII antibody is un-conjugated

Application

  • 67
  • 40
  • 39
  • 39
  • 39
  • 26
  • 16
  • 10
  • 9
  • 7
  • 6
  • 4
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Clone

MH104
  • Specificity

    MH104 is specific for human factor VIIIc, a 300 kDa protein present in plasma in a complex with von Willebrandt factor. Involved in the clotting cascade (activated by thrombin) by forming a complex with factor IXa, calcium, and phospholipids. Elevated levels of factor VIII have been associated with acute and chronic liver diseases, vascular disorders, diabetes and with acutephase reactions.

    Purification

    Protein A affinity chromatography

    Immunogen

    Human factor VIII antigen

    Isotype

    IgG2a
  • Application Notes

    ELISA: 1: 5,000, detection and quantitation of human factor VIII. Immunoblotting. Immunohistochemistry on frozen sections.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.

    Restrictions

    For Research Use only
  • Reconstitution

    Restore in 1 mL dist. water

    Buffer

    PBS, pH 7.4 containing 0.09 % NaN3, 0.5 % BSA

    Preservative

    Sodium azide

    Precaution of Use

    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Handling Advice

    This product is photosensitive and should be protected from light

    Storage

    4 °C

    Storage Comment

    Prior to and following reconstitution store the antibody undiluted at 2-8 °C. DO NOT FREEZE!
  • Target

    Factor VIII (F8) (Coagulation Factor VIII (F8))

    Background

    Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50 % of patients have severe hemophilia A with F8C activity less than 1 % of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10 % of patients, F8C activity is 2-5 % of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40 % of patients, is associated with F8C activity of 5-30 % and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5 %) that have considerable amount of F8C in their plasma (at least 30 % of normal), but the protein is nonfunctional, i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component

    Gene ID

    2157

    NCBI Accession

    NP_000123

    UniProt

    P00451
You are here:
Chat with us!